Navigation Links
BioMarin to Present at the Barclays Capital Global Healthcare Conference
Date:3/4/2009

NOVATO, Calif., March 4 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in Miami on Wednesday, March 11th, 2009 at 2:30 p.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                         Media
    Eugenia Shen                      Susan Berg
    BioMarin Pharmaceutical Inc.      BioMarin Pharmaceutical Inc.
    (415) 506-6570                    (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
2. BioMarin Supports Observance of Rare Disease Day February 28
3. BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
5. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
6. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
7. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
8. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
9. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
10. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
11. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Virginia Washington, DC (PRWEB) , ... ... ... Media Contact: Claudia Tellez, Executive Director 703.462.0658, ctellez(at)msnva.org , The Medical Society ... for community physicians and their patients , The Medical Society of Northern ...
(Date:5/5/2016)... ... , ... Linfield College Online and Continuing Education is encouraging registered nurses to ... fee for all qualified applicants from May 1–14. Students need only go to the ... . , With the RN to BSN degree program, all core ...
(Date:5/5/2016)... FL (PRWEB) , ... May 05, 2016 , ... In ... is easy to forget the most important arrangement — planning a safe way of ... celebrations and popular tequila drinks. Unfortunately, these celebrations often lead to drunk drivers on ...
(Date:5/5/2016)... ... May 05, 2016 , ... Is the part in your ... just a few days away, it’s a good opportunity to raise awareness about a ... American Academy of Dermatology, 40% of women experience hair loss or ‘thinning’ by the ...
(Date:5/5/2016)... ... May 05, 2016 , ... BloodHub, the nation’s ... service orders. Blood suppliers and their hospitals use BloodHub for order management, ... active users across 2,100 hospitals who use our platform to processes thousands of ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute Myeloid Leukemia Market and ... their offering.       (Logo: ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Myeloid Leukemia epidemiology, Acute ...
Breaking Medicine Technology: